Krishna Institute of Medical Sciences (KIMS) added 2.10% to Rs 2148 after the company executed a share purchase agreement (SPA) to acquire 100% equity stake of Chalasani Hospitals Private for total consideration of Rs 75 crore.

KIMS gains after inking pact to acquire 100% stake in Chalasani Hospitals

Krishna Institute of Medical Sciences (KIMS) said that its board has approved the proposal for the sub-division of one equity share of the company having a face value of Rs 10 each into five equity shares having a face value of Rs 2 each.

KIMS Hospitals board grants nod to 1:5 stock split proposal

Shares of Krishna Institute of Medical Sciences (KIMS) shot up to 6.4 per cent at Rs 2187 per share on the BSE in Tuesday’s intraday deals

KIMS share price zooms 6% after proposing stock split; details here

The company through its investment in Meda Institute of Podiatry aims to set up and expand small Podiatric hospital clusters to ensure that the infrastructure meets the specific needs of podiatric care, in Hyderabad, India.

Krishna Institute of Medical Sciences to invest Rs 1.02 cr in Meda Institute of Podiatry

Krishna Institute of Medical Sciences consolidated profit after tax stood at Rs 77 crore, down 6.7%% YoY, which was led by low operating profitability during the quarter.

KIMS Q3 Results Review - Strong Operating Cash Flows, ROCE: Axis Securities

Prabhudas Lilladher is bullish on Krishna Institute of Medical Sciences has recommended buy rating on the stock with a target price of Rs 2000 in its research report dated November 08, 2023.

Buy Krishna Institute of Medical Sciences; target of Rs 2000: Prabhudas Lilladher

The report is based on the agency’s sample of nine listed hospital chains -- Apollo Hospitals, Aster DM Healthcare, Fortis Healthcare, Healthcare Global Enterprises, Krishna Institute of Medical Sciences, Max Healthcare, Narayana Hrudayalaya, Rainbow Children’s Medicare and Shalby Hospital.

Corporate hospitals to see 8-10 pc revenue growth in FY24: Report

Prabhudas Lilladher is bullish on Krishna Institute of Medical Sciences has recommended buy rating on the stock with a target price of Rs 2000 in its research report dated August 09, 2023.

The stock has given a short-term breakout.

Buy Krishna Institute of Medical Sciences., target price Rs 1950: Jayesh Bhanushali

Hyderabad-based Krishna Institute of Medical Sciences reported a 15.5 percent YoY rise in Q1 consolidated profit to Rs 80.8 crore driven by a healthy topline.

KIMS declines despite a profitable Q1

Krishna Institute of Medical Sciences (KIMS) plans to expand to 8,000 beds in 2-3 years in Telangana, AP, Maharashtra and Karnataka. Expansion includes new therapies, departments and units in Visakhapatnam, Secunderabad, Nagpur. Consolidation of Sunshine Hospitals yielded 19% revenue contribution.

KIMS to double number of beds to 8,000 in 2 years

Hasn't fared well - amongst the low performers

Performance

Seems to be overvalued vs the market average

Valuation

Financials growth has been moderate for a few years

Growth

Showing good signs of profitability & efficiency

Profitability

The stock is underpriced and is not in the overbought zone

Current price is less than the intrinsic value

Fundamentals

Good time to consider, stock is not in the overbought zone

Technicals

Entry point

Promoter pledged holding

Unsolicited messages

Default probability

Red flags

Krishna Institute of Medical Sciences Ltd is engaged in the business of rendering medical and healthcare services. Its hospital network is spread across Andhra Pradesh,Telangana, Karnataka, Odisha, Tamil Nadu and Central India.